



CONGRESSIONAL BUDGET OFFICE
COST ESTIMATE

September 17, 2014

H.R. 4299
Improving Regulatory Transparency for New Medical Therapies Act

*As ordered reported by the House Committee on the Judiciary
on September 10, 2014*

H.R. 4299 would modify the administrative procedures followed by the Department of Justice in regulating new drugs that are already approved by the Food and Drug Administration and in authorizing drugs to be used in clinical trials. The legislation would aim to streamline the current review and approval process. CBO estimates that implementing the bill would have no significant costs to the federal government. Enacting the legislation would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply.

H.R. 4299 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act and would impose no costs on state, local, or tribal governments.

On June 26, 2014, CBO transmitted a cost estimate for H.R. 4299 as ordered reported by the House Committee on Energy and Commerce on June 10, 2014. The cost estimates are the same.

The CBO staff contact for this estimate is Mark Grabowicz. The estimate was approved by Theresa Gullo, Deputy Assistant Director for Budget Analysis.